CONCORD, Calif. - Cerus (NASDAQ:CERS) Corporation (NASDAQ:CERS), a company focused on blood supply safety, announced Monday the appointment of Dean Gregory to its Board of Directors. Gregory, with over three decades of experience in the blood transfusion and cell therapy sectors, recently retired from his role as President of Global Commercial Operations at Fresenius Kabi, a leading medical technology company.
The addition of Gregory is seen as a strategic move for Cerus as it aims to broaden the adoption of its INTERCEPT Blood System and enhance its manufacturing capabilities to meet growing demand. The INTERCEPT technology is designed to reduce pathogens in blood components, ensuring safer transfusions.
Daniel Swisher, Chair of the Board, expressed confidence that Gregory's extensive background will provide valuable insights and support Cerus’s growth initiatives, especially in expanding the INTERCEPT Blood System's reach and advancing its Red Blood Cell program.
Gregory's career includes significant contributions to the transfusion medicine field, marked by leadership positions at Fenwal Inc. and a 15-year tenure at Baxter International (NYSE:BAX), where he was involved in commercial and business development roles.
Cerus’s INTERCEPT Blood System is the only pathogen reduction system that has received both CE mark and FDA approval for platelets and plasma. The company is also developing a pathogen-reduced red blood cell system, which is currently under regulatory review in Europe and in late-stage clinical development in the U.S.
This news is based on a press release statement from Cerus Corporation, which continues to innovate in the realm of blood product safety and availability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.